Indications for: PERFOROMIST

Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema.

Limitations of Use:

Not indicated to treat acute deteriorations of COPD or for treatment of asthma.

Adult Dosage:

20micrograms (1 vial) by nebulizer twice daily (AM & PM). Use standard jet nebulizer (eg, PARI-LC Plus [with face-mask or mouthpiece]) and air compressor (eg, Proneb Ultra compressor). Does not need to be diluted before nebulization. Do not mix with other drugs.

Children Dosage:

Not established.

PERFOROMIST Contraindications:

Use of LABA without inhaled corticosteroid (ICS) in asthma.

PERFOROMIST Warnings/Precautions:

LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in acute deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Cardiovascular disease (esp. hypertension, coronary insufficiency, arrhythmias). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Pregnancy. Labor & delivery. Nursing mothers.

PERFOROMIST Classification:

Long-acting beta-2 agonist (LABA).

PERFOROMIST Interactions:

Caution with concomitant other adrenergic drugs; may potentiate sympathetic effects. Extreme caution with MAOIs, tricyclics, or others that prolong QTc interval (may cause ventricular arrhythmias). Antagonized by β-blockers. K+-depleting diuretics, xanthines, steroids may potentiate hypokalemia.

Adverse Reactions:

GI upset, nasopharyngitis, dry mouth, dizziness, insomnia; ECG changes or cardiovascular effects (eg, increased BP, tachycardia; consider discontinuing if occur); hypokalemia, hyperglycemia, metabolic acidosis; hypersensitivity reactions; rarely: paradoxical bronchospasm.

Generic Drug Availability:


How Supplied:

Single-use vials (2mL)—30, 60